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Meier-Gorlin syndrome (MGS) is a genetically heterogeneous primordial dwarfism syndrome known to be caused by biallelic loss-of-
function mutations in one of five genes encoding pre-replication complex proteins: ORC1, ORC4, ORC6, CDT1, and CDC6. Mutations
in these genes cause disruption of the origin of DNA replication initiation. To date, only an autosomal-recessive inheritance pattern has
been described in individuals with this disorder, with a molecular etiology established in about three-fourths of cases. Here, we report
three subjects withMGS and de novo heterozygous mutations in the 50 end of GMNN, encoding the DNA replication inhibitor geminin.
We identified two truncating mutations in exon 2 (the 1st coding exon), c.16A>T (p.Lys6*) and c.35_38delTCAA (p.Ile12Lysfs*4), and
one missense mutation, c.50A>G (p.Lys17Arg), affecting the second-to-last nucleotide of exon 2 and possibly RNA splicing. Geminin is
present during the S, G2, andM phases of the cell cycle and is degraded during the metaphase-anaphase transition by the anaphase-pro-
moting complex (APC), which recognizes the destruction box sequence near the 50 end of the geminin protein. All three GMNNmuta-
tions identified alter sites 50 to residue Met28 of the protein, which is located within the destruction box. We present data supporting a
gain-of-function mechanism, in which the GMNNmutations result in proteins lacking the destruction box and hence increased protein
stability and prolonged inhibition of replication leading to autosomal-dominant MGS.Meier-Gorlin syndrome (MGS [MIM 224690, 613800,
613803, 613804, 613805]) is recognized as an autosomal-
recessive disorder characterized by dwarfism, absent or hy-
poplastic patellae, and microtia.1,2 Additional phenotypic
features include pulmonary emphysema, feeding diffi-
culties, urogenital abnormalities, mammary hypoplasia,
and characteristic facial features.3 The hallmark of distinct
ear abnormalities and full lips, down-slanting palpebral
fissures, narrow nose, high nasal bridge, microstomia,
and micro/retrognathia distinguish this genetic disorder,
enabling clinical diagnosis in most cases.4,5 Intellectual
disability or cognitive deficits are rare in MGS.4,5
Human subjects manifesting a MGS clinical phenotype
have provided important insights into DNA replication
mechanisms and both cell and organism growth. MGS is
a form of microcephalic primordial dwarfism, and thus,
the syndrome is associated with proportionate growth def-
icits with microcephaly.4 These growth deficits are noted
prenatally and persist postnatally.4,5 Pathogenic changes
in one of five genes that encode pre-replication complex
proteins, namely ORC1 (MIM: 601902), ORC4 (MIM:
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MGS.6–8 Of these five genes, three (ORC1, ORC4, ORC6)
encode proteins that are members of the origin of replica-
tion complex which consists of six proteins (ORC1–ORC6)
that bind to origins of replication and initiate the process
of DNA replication.9,10 Binding of the six members of
the origin of replication complex then recruits the DNA
replication factors CDT1 and CDC6, which facilitates
loading of the mini-chromosome maintenance (MCM)
helicase.11–13 During S phase of the cell cycle, MCM heli-
case unwinds DNA and allows for the initiation of replica-
tion.14 It is hypothesized that the autosomal-recessive
forms of MGS result from hypomorphic alleles because
no homozygous or compound heterozygous loss of func-
tion mutations have been described in individuals with
this syndrome.5 Defects in this process of the initiation
of DNA replication are the primary mechanism underlying
growth failure in this disorder. However, mutations in the
five pre-replication complex genes only explain the
phenotype in approximately 78% of individuals with a
clinical diagnosis of MGS.4,6–8 The molecular etiology in
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Table 1. Clinical Features of the Three Subjects with De Novo Heterozygous GMNN Mutations
Phenotype Subject 1 Subject 2 Subject 3
Sex Female Male Female
Age at diagnosis 5 months 4 months 3 years
Age at recent examination 34 months 17 years 3 years and 4 months
Prematurity Yes (32 4/7 weeks) No (38 2/7 weeks) No (38 5/7 weeks)
Classic Triad
Short stature (Height Z score) 67.5 cm (6.8)a 150.3 cm (3.9)22,b 76.5 cm (6.0)23
Microtia Yes Yes Yes
Patella aplasia Yes Yes Yes
Growth Parameters
Birth weight (Z score) 980 g (2.2)19 1900 g (3.5)24 2750 g (1.1)24
Birth length (Z score) NA 40 cm (4.9)24 45 cm (2.2)24
Birth head circumference NA 30.5 cm (2.7)24 NA
Weight on examination (Z score) 5.6 kg (11.98)a 36.4 kg (3.0)22 7.7 kg (3.1 (weight for length))23
Head circumference on
examination (Z score)
45.5 cm (1.9)20,a NA 43.5 cm (3.8)24
Delayed bone age Yes Yes NA
Facial Characteristics
Frontal bossing or high forehead Yes Yes Yes
Down-slanted palpebral fissures Yes No No
Posteriorly rotated ears Yes No Yes
Upturned nose Yes No No
Hypoplastic nares Yes Yes Yes
Full lips Yes Yes Yes
Micro-/retrognathia Yes Yes Yes
Neurologic Features
Motor delay No Yes Yes
Speech delay No Yes Yes
Developmental assessment NA IQ ¼ 61 (at age 14 years) IQ ¼ 59 (at age 10 years)
Respiratory Features
Pulmonary emphysema No Yes No
Laryngomalacia Yes No No
Tracheo-/Bronchomalacia Yes No No
Gastrointestinal Features
Feeding problems in infancy Yes Yes Yes
Failure to thrive Yes Yes No
Gastresophageal reflux Yes No No
Urogenital Anomalies
Abnormal genitalia Yes No NA
Hypospadias NA No NA
Cryptorchidism NA Yes NA
Hypoplastic labia majora Yes NA NA
Renal anomalies NA No No
(Continued on next page)
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Table 1. Continued
Phenotype Subject 1 Subject 2 Subject 3
Other Trichiasis Nanophthalmos Increased/marked lumbar
lordosis Urethral stenosis/
dysplasia
Increased/marked lumbar
lordosis
Bilateral congenital hip
subluxation
Strabismus
Cleft palate (palatum molle)
Abbreviations are as follows: NA, Not available.
aNot corrected for gestational age, CDC 2000 growth chart.
bAfter use of growth hormone therapy.We now describe three subjects with a simplex auto-
somal-dominant form of MGS who carry de novo hetero-
zygous mutations in the 50 end of GMNN (MIM: 602842).
GMNN maps to 6p22.3 and encodes the DNA replication
inhibitor geminin. Geminin regulates cell-cycle progres-
sion and replication by interacting with the DNA replica-
tion factor CDT1, which is encoded by a gene with a
known association to MGS, CDT1.15–18 Written informed
consent was obtained in accordance with protocols
approved by the appropriate human subjects ethics com-
mittees at Baylor College of Medicine and Radboud univer-
sity medical center. A summary of clinical findings in all
three subjects is provided in Table 1.
Subject 1 was born at 32 4/7 weeks gestation by emer-
gency cesarean section. Family history revealed that the
mother had multiple spontaneous miscarriages. There
was no known consanguinity. The pregnancy was compli-
cated by twin gestation, placental insufficiency and severe
intrauterine growth restriction in the proband. Her birth
weight was 980 g (Z score ¼ 2.2).19 The proband had a
prolonged hospitalization of about 2 months due to
feeding issues necessitating nasogastric tube feeding, and
she was diagnosed with gastresophageal reflux. She was
hospitalized again at 5 months of age for failure to thrive.
She had cochlear implants placed for conductive hearing
loss secondary to aural atresia/microtia and was diagnosed
with grade II subglottic stenosis, tracheomalacia, and bron-
chomalacia by diagnostic bronchoscopy and laryngos-
copy. She had delayed bone age (3.5 SD from mean for
age) with low IGF1 and normal IGFBP-3. Brain magnetic
resonance imaging (MRI) study showed a mildly simplified
gyral pattern with delayed myelination even after correc-
tion for prematurity. She continued to meet her develop-
mental milestones as expected for age. When evaluated
again at 2 years 9 months of age, her growth parameters re-
mained below the expected range for her age (Table 1).19,20
Other distinct craniofacial findings included frontal boss-
ing, downslanting palpebral fissures, bilateral entropion,
upturned nose with hypoplastic nares, severe microtia
with no external auditory canal openings, midface hypo-
plasia, full lips, and micrognathia (Figure 1). She also had
absent patellae bilaterally, midphalangeal hypoplasia of
the 5th digit of the upper extremities bilaterally, single
transverse palmar crease on the right hand, under-devel-
oped distal finger creases, sandal gap between first two906 The American Journal of Human Genetics 97, 904–913, Decembtoes bilaterally, a small umbilical hernia, and hypoplastic
female genitalia. Given her features of microtia, absent
patellae, and short stature/primordial dwarfism, a clinical
diagnosis of MGS was made. Chromosome microarray
(Baylor version 8.3) was normal, and whole-exome
sequencing was performed.
Subject 2 (Figure 1) was previously described by Bongers
et al. (patient 2) and de Munnik et al. (patient 43).3,5 His
short stature has persisted, and he has been diagnosed
with growth hormone deficiency. Growth hormone was
initiated at age 3 years (height 6.8 SD) and ended at
14 years (height 3 SD). In addition, he was diagnosed
with delayed puberty. Puberty was induced with testos-
terone at the age of 13.5 years, but his progression
through puberty has remained slow. His growth parame-
ters at most recent physical examination are presented
in Table 1. His pulmonary complications ultimately led
to a diagnosis of congenital emphysema. In addition,
his developmental delays persisted, and a full develop-
mental assessment revealed an IQ of 61. Karyotype anal-
ysis and molecular testing of the five known MGS genes
were normal.
Subject 3 was the first child of healthy, non-consanguin-
eous Dutch parents. The infant was delivered in the
occiput posterior position at 38 5/7 weeks. Her birth
weight was 2,750 g (Z score 1.1),21 and her birth length
was 45 cm (Z score 2.2).22 She had a cleft palate, feeding
difficulties and required nasogastric tube feeds. Moreover,
she was diagnosed with congenital hip dysplasia, stra-
bismus convergens, and recurrent respiratory infections.
Psychomotor development, especially speech, was mildly
delayed. Growth parameters assessed during the most
recent visit are presented in Table 1.23,24 Other findings
on physical examination included posteriorly rotated
ears with a simple shape and narrow auditory canals, small
nose with flat nasal bridge, aplastic patellae, feet in a plano-
valgus position, and marked lumbar lordosis (Figure 1).
Echocardiogram and renal ultrasound were normal. The
combination of short stature, absent patellae, and microtia
led to a clinical diagnosis of MGS. Karyotype analysis and
Sanger sequencing for the five genes with known associa-
tions to MGS, CHD7 (MIM: 608892) for CHARGE syn-
drome (MIM: 214800), and TCOF1 (MIM: 606847) for
Treacher Collins syndrome (TCS1 [MIM: 154500]) revealed
no abnormalities.er 3, 2015
Figure 1. Phenotypic Features of Sub-
jects with GMNN Mutations
(A) Subject 1 with frontal bossing, fine
facial features, downslanting palpebral fis-
sures, bilateral entropion, upturned and
beaked nose with hypoplastic nares, full
lips, and micrognathia.
(B) Bilateral microtia with posteriorly
rotated ears (subject 1).
(C) Knees with absent patellae (subject 1).
(D) Subject 2 with high forehead, short
palpebral fissures with long eyelashes,
small mouth with full lips, micrognathia,
and prominence of the veins over both
nose and forehead.
(E) Small and simple ear with small
external auditory canals (subject 2).
(F) Subject 3 with high forehead, medial
sparse/decreased eyebrows, upturned nose
with hypoplastic nares, full lips, and
micrognathia.
(G) Microtia with posteriorly rotated ears,
hypoplastic nares, convex profile of the
nose, everted lower lip, and micrognathia
(subject 3).Whole-exome sequencing (WES) was completed in the
Exome Laboratory at Baylor Miraca Genetics Laboratories
(subject 1) and at Baylor College of Medicine Human
Genome Sequencing Center (BCM-HGSC) through the
Baylor Hopkins Center for Mendelian Genomics (subject
2) (Table S1). Sequencing and data analyses were conduct-
ed as previously described, targeting approximately 20,000
genes, including the coding and UTR exons.25–27 Seq-
uencing data from Illumina HiSeq 2000 were mapped
to the reference haploid human genome sequence
(GRCh37/hg19) using the Burrows-Wheeler Alignment
(BWA) algorithm.28 Variant calling from the aligned
BAM files was performed using the in-house developed
ATLAS2 suite.29 Annotation was performed using the
in-house developed annotation pipelines CASSANDRA
and SACBE that make use of ANNOVAR and custom
scripts.29,30 Variants were classified into exonic, intronic,
or intergenic as well as their potential functional effects,
and their frequencies in different populations and data-
bases by the mentioned annotation pipelines. VariantsTable 2. Summary of GMNN Mutations in Three Unrelated Subjects w
Subject
Coordinate
(hg19)
Mutation
Type
Nucleotide
Change
Predicted Amin
Acid Change
1 Chr6:
24777490
Stop gain c.16A>T p.Lys6*
2 Chr6:
24777509-
24777512
Frameshift
deletion
c.35_38delTCAA p.Ile12Lysfs*4
3 Chr6:
24777524
Missense c.50A>G p.Lys17Arg
aExon 2 is the first coding exon for GenBank NM_015895.4.
bNR, not reported.
cPredicted to affect downstream splicing at the exon 2 and intron 2 boundary.
dNA, not applicable.
The Americanwere filtered by their observed frequencies in databases
including dbSNP, the 1000 Genomes Project, and the
NHLBI Exome Sequencing Project Exome Variant Server
(EVS) to filter out common polymorphisms of high fre-
quency in healthy control populations that are likely to
be benign variants.25,27
Whole-exome sequencing identified a heterozygous
c.16A>T (p.Lys6*) nonsense (stopgain) mutation in
GMNN (GenBank: NM_015895.4) of subject 1 and a het-
erozygous c.35_38delTCAA (p.Ile12Lysfs*4) frameshift
deletion in the same gene of subject 2, which is predicted
to result in a premature stop four positions downstream
(Table 2, Figure 2). To determine whether mutations in
GMNN are present in other individuals with MGS, we per-
formed subsequent Sanger sequencing of all coding re-
gions and splice sites ofGMNN in seven additional subjects
at the Radboud university medical center with suspected
MGS but without a molecular diagnosis (Table S2). In sub-
ject 3, we identified a missense mutation in the second-to-
last nucleotide of exon 2, c.50A > G (p.Lys17Arg), whichith Meier-Gorlin Syndrome
o
Exon Inheritance
ExAC
Frequency
Mutation
Taster ESE Finder
2 a de novo NRb deleterious NAd
2 a de novo NRb deleterious NAd
2 a de novo NRb deleteriousc Elimination
of SRSF5
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Figure 2. GMNN Mutations in the Three
Families with Meier-Gorlin Syndrome
and the Predicted Effects
(A) Sanger sequencing of genomic DNA
from peripheral blood of subjects 1, 2, 3,
and parents suggesting the three muta-
tions occurred de novo in the probands.
The genotypes are shown below each indi-
vidual with ‘‘þ’’ representing the wild-type
allele and ‘‘mt’’ representing the mutant
allele.
(B) Annotation of the three amino acid
residues in exon 2 (Lys6, Ile12, Lys17)
affected in the subjects shows conservation
across different species. Ile12 is the least
conserved; however, it is a frameshift
mutation that is predicted to affect not
only Ile12 but also result in a premature
stop four positions downstream. The
p.Lys17Arg substitution is predicted to
disrupt splicing possibly leading to either
skipping of exon 2 or retention of intron
2 and introduction of a premature stop
codon (TGA) in intron 2 that is highlighted
with a blue box.
(C) ESE Finder predicted the downstream
effects of the c.50A>G (p.Lys17Arg) muta-
tion in subject 3. Different exonic splicing
enhancer (ESE) motifs represented in
different colors are listed in the lower
boxes with SFRS5 represented in green.
The mutant sequence (ATAAGGg, right
panel) was predicted to result in loss of
SFRS5, which presented in the wild-type
sequence (ATAAAGg, left panel) with a
score of 3.39 (threshold 2.67). The thresh-
olds are values above which a score for a
given sequence is considered to be signifi-
cant (high-score motif).was predicted to eliminate an exonic splice enhancer (ESE)
target site of serine/arginine-rich splicing factor 5 (SRSF5)
by ESE Finder (Table 2, Figure 2).31,32 The downstream
splice site at the exon 2 and intron 2 boundary was also
predicted to be diminished by another in silico prediction
program, Mutation Taster (Table 2, Figure 2).33 All three
changes were located in exon 2, which is the first coding
exon of GMNN (GenBank: NM_015895.4).
Sanger sequencing confirmed the heterozygous muta-
tions in the subjects and showed that the mutations were
absent in DNA samples from all biological parents in the
three families, indicating that the three mutations arose
de novo in the subjects (Figure 2). Moreover, the mutation
was not identified in a sample from the unaffected twin
of subject 1. These mutations were not found in control
databases including the 1000 Genomes Project and Exome908 The American Journal of Human Genetics 97, 904–913, December 3, 2015Aggregation Consortium (ExAC) data-
bases. Moreover, we were unable to
detect any likely contributing muta-
tions by exome sequencing in the
five genes previously reported to har-
bor mutations that cause MGS or in
other candidate genes such as ORC2(MIM: 601182), ORC3 (MIM: 604972), and ORC5 (MIM:
602331) encoding other members of the origin of replica-
tion complex in subjects 1 and 2. In subject 3, we previ-
ously excluded the five known MGS genes by Sanger
sequencing. In summary, three distinct, rare and likely
pathogenic de novo alleles were identified in the same
gene in three unrelated subjects with the same rare clini-
cally recognizable disease trait. Our data suggested that
GMNN dysfunction is the most likely molecular explana-
tion for the subjects’ phenotypes.
GMNN encodes geminin, a nuclear regulator protein that
is a known inhibitor of replication.34 Geminin is present
during S, G2, andM phases of the cell cycle but is degraded
as cells exit mitosis, and it is absent in G1 when origins of
replication are licensed.34 During S phase, geminin binds
DNA replication factor CDT1 and prevents MCM helicase
Figure 3. Positions of the Early GMNN
Mutations and Destruction Signal in
Geminin
The early de novo mutations could lead
to elimination of the destruction signal
(boxed) with use of Met28 as an alternative
initiation codon. Affected amino acids are
represented in red; start codon (Met1),
the proposed alternative start codon
(Met28), and residues Met4 and Met89
are represented in green. The amino acids
encoded by exon 2 and exon 3 of GMNN
are in separate brackets with exon numbers
labeled above.from loading onto origins of replication and thus prevents
re-licensing of origins of replication.15,16 In addition, gem-
inin inhibits histone acetyltransferase HB01, and this inhi-
bition, which requires CDT1, is believed to be another
mechanism by which geminin and CDT1 regulate cell-cy-
cle progression, in particular, re-replication licensing.17,18
The degradation of geminin at the end of mitosis is medi-
ated by a nine-amino-acid destruction box at the N termi-
nus of the protein from Arg23 to Pro31 (RRTLKMIQP),
which is encoded by DNA sequences in exon 3 of GMNN
and located downstream of the three exon 2 mutations
identified in this study (Figure 3).34 The destruction box
sequence is ubiquitinated by the anaphase-promoting
complex (APC), resulting in protein degradation at the
end of mitosis.34 Previous studies showed that when this
destruction box is absent, the half-life of geminin is
increased, and cell proliferation is inhibited in vitro.34–36
The heterozygous de novomutations identified in exon 2
of GMNN in subjects 1 and 2 are predicted to result in pre-
mature stops that occur before the destruction box encoded
by exon 3.34 In subject 3, the de novo substitution, which is
also located before the destructionbox sequence, affects the
second-to-last nucleotide of exon 2 and predicted a moder-
ately conservative missense change of lysine to arginine,
because both are di-basic amino acids. However, this muta-
tion is also predicted to result in aberrant splicing possibly
leading to either skipping of exon 2 or retention of intron
2 and introduction of a premature stop codon (TGA) in
intron 2 (Figure 2). Further studies for subject 3 using pe-
ripheral blood samples or cultured cells to assess the effects
of the mutation at the cDNA level were not conducted as
they were not consented by the family.
For subjects 1 and 2, we conducted transcriptional
studies on cells from each subject to monitor the effect
of the mutations at the mRNA level. PCR amplification
and Sanger sequencing of cDNA generated from lympho-
blast-derived cell lines (subjects 1 and 2) as well as cultured
fibroblasts (subject 2) demonstrated the presence of the
mutant transcript with approximate 1:1 ratios of the
wild-type and mutant alleles (Figure S1) suggesting that
the mutant transcript is stable and escapes nonsense medi-
ated decay (NMD). To corroborate this observation, weThe Americancloned GMNN RT-PCR product of subject 1 using TOPO
TA-cloning (Invitrogen) and Sanger sequenced eight indi-
vidual clones. Of the sequenced clones, 50% (4/8 clones)
harbored the mutant allele c.16A>T (p.Lys6*) and the
other 50% (4/8 clones) harbored the wild-type allele
(Figure S1). Because RNA studies demonstrated that the
mutant alleles did not appear to be subject to NMD, in
the setting of early truncation, we hypothesize that an
alternative start codon at residue Met28, which is located
in exon 3 within the destruction box and downstream of
the exon 2 mutations (Figure 3), might be used for transla-
tion initiation in the subjects resulting in a protein lacking
the 27 amino acids at the N terminus includingmost of the
destruction box. Western blot analysis of protein lysates
from subject 1 lymphoblast-derived cell lines offered pre-
liminary confirmation of this posit; we detected both full
length and truncated GMNN isoforms using a previously
described antibody raised against the full-length human
protein (Figure S2).35
To investigate further whether the AUG codon corre-
sponding to Met28 in subject 1 and 2 can be used as an
alternative start codon, we tagged mutant GMNN cDNA
as well as the wild-type GMNN cDNA with a HA epitope
at the N terminus and a V5 epitope at the C terminus.
Themutation in subject 3 was not studied because its effect
on cDNA cannot be determined due to lack of consent for
further research studies. Both in vitro and ectopic expres-
sions of the GMNN mutants produced a truncated protein
4–5 kDa shorter than the wild-type protein, consistent
with what would be predicted if the translation starts
from the Met28 residue (Figures 4A and 4B). Additionally,
the wild-type GMNN construct produced a full-length pro-
tein with both the HA and V5 epitopes, whereas mutant
GMNN constructs produced truncated proteins tagged
only with V5 at the C terminus but lacking the HA epitope
at the N terminus, consistent with the translation initia-
tion at the downstream Met28 (Figures 4A and 4B).
Although we also detected additional products predicted
to be translated from Met89 further downstream in the
in vitro assays (Figure 4A), the resulting protein is predicted
to lack the interaction domain with CDT1 and is thus un-
likely to be functional.Journal of Human Genetics 97, 904–913, December 3, 2015 909
Figure 4. GMNN Mutations Produce a
More Stable Protein Starting at Residue
Met28with theDestruction Box Eliminated
(A) Western blot of geminin proteins from
in vitro transcription and translation: GFP
is used as a positive control for the reaction.
Kozak-GFP (lane 1): GFP control with
optimal Kozak sequence (for translation
initiation); endogenous GFP (lane 2): GFP
control with human GMNN endogenous
Kozak sequence; HA-hGMNNWT-V5 (lane
3), HA-hGMNNm1-V5 (lane 4), and HA-
hGMNNm2-V5 (lane 5): human GMNN
from wild-type, subject 1, and subject 2,
respectively, carrying endogenous Kozak
sequence and tagged with N-terminal HA
epitope and C-terminal V5 epitope;
hGMNNWT-V5 (lane 6), hGMNNm1-V5
(lane 7), and hGMNNm2-V5 (lane 8): hu-
man GMNN from wild-type, subject 1, and
subject 2 respectively carrying endogenous
Kozak sequence and tagged only with C-ter-
minal V5 epitope (this is designed for
testing the translation preference for the
start codon staring fromHA). Same amount
of templates (69 ng) are used in each reac-
tion. Our data showed the mutant con-
structs produced a truncated protein of
4–5 kDa shorter than the wild-type protein,
consistent with what would be predicted
if the translation starts from Met28 residue
(lanes 3–7). Although there is also pro-
duct translated from the 4th start codon
(p.Met89), it lacks CDT1 interaction
domain and is thus likely to be non-func-
tional. Wild-type GMNN construct can be
translated into a full-length protein with
both HA and V5 epitopes while mutant
GMNN constructs can only produce trun-
cated protein with V5 tag, but not HA tag.
The HA-tagged products from both mutant GMNN constructs would be too small and thus are not presented on the Western blot.
(B) Western blot of ectopically expressed geminin in HEK293T cells. GMNN cDNA of wild-type, subject 1, and subject 2, are cloned
into the pCMV-HA expressing vector and are also tagged with V5 epitope at C terminus. GFP is co-transfected in every condition as a
transfection internal control and GAPDH is used as loading control. We again observed that the mutant constructs produced a truncated
protein that would be expected if the translation starts from Met28 residue. Wild-type GMNN construct can be translated into a full-
length protein with both HA and V5 epitopes while mutant GMNN constructs can only produce truncated protein with V5 tag but not
HA tag.
(C) Western blot analysis of protein stability of the ectopically expressed proteins in HEK293T cells. The transfected cells were treated with
cycloheximide (CHX, 100 mg/ml, blocker of protein synthesis) or CHX plusMG132 (10 mM, inhibitor of proteasome) and lysed at 0, 3, and
6 hr. The Western blot data showed that CHX treatment revealed degradation of the wild-type protein, while no obvious degradation was
observed in mutant proteins under the same conditions indicating that the mutant proteins, which were translated using Met28 as the
start andwithout the destruction box, weremore stable. The addition ofMG132 conferred stability for bothwild-type andmutant proteins
as no obvious degradation was observed for protein with the CHX plusMG132 treatment. In (B) and (C), asterisks denote that the product
is likely to be a posttranslational modification or dimer since this is not recognized by HA but only V5 antibody and the molecular weight
of the top band is slightly different from the wild-type protein.To compare the stability of the wild-type and mutant
proteins, the transfected HEK293T cells were treated with
cycloheximide (CHX, which blocks protein synthesis) or
CHX plus MG132 (a proteasome inhibitor), and lysed at
0, 3, and 6 hr. Western blot data showed that CHX treat-
ment led to degradation of the wild-type protein, while
no obvious degradation was observed in mutant proteins
under the same conditions, indicating that the mutant
proteins, which were translated using Met28 as the start
and without the intact destruction box, were more stable
(Figure 4C). For both wild-type and mutant proteins, no910 The American Journal of Human Genetics 97, 904–913, Decembobvious degradation was observed when treated with the
CHX plusMG132 (Figure 4C), consistent with the reported
role of the proteasome in geminin degradation and sug-
gesting that lack of the destruction box signal confers sta-
bility for the protein.
We also performed flow cytometry to investigate the dis-
tribution of cells in different cell-cycle phases in asynchro-
nous lymphoblasts of subject 1 and her father (as a control)
(Figure S3). The percentages of cells (average from the trip-
licate studies) in G1 phase were 60% and 48% in cells from
subject 1 and the control respectively (p ¼ 0.0005) whileer 3, 2015
the percentages in S phase were 23% and 32% in subject 1
and the control, respectively (p ¼ 0.0024). Although we
observed a small increase in G1 content in subject 1, it is
unknown whether the mutant geminin causes delayed
S-phase entry, as previously observed in ORC1-deficient
cells.6 Additional investigations on the mutant geminin
protein’s effects on the cell cycle and its expression in vivo
are warranted in order to further understand its role in
MGS pathogenicity.
Interestingly, the usage of the same alternative start
codon (Met28) and increased geminin stability was also
observed in a previous study, which showed that an engi-
neered mutation abolishing the original translation start
site of geminin in vitro results in a truncated protein that
likely resulted from use of the same Met28 alternative start
codon in a human colon cancer cell line.35 When Met28,
which is located within the destruction box, is used as
the alternative start codon, the destruction box is elimi-
nated, resulting in increased protein stability and
decreased replication.35 Deletions involving the destruc-
tion box sequence in Xenopus produce similar results
in vitro.34 A partial rescue of these phenotypes occurs
with overexpression of CDT1.35
As the most parsimonious explanation of the aggregate
data, we propose that the de novo GMNNmutations iden-
tified in the subjects result in truncated proteins (initiated
at residue Met28) lacking the destruction box, leading to
increased geminin protein stability and prolonged inhibi-
tion of replication. The mutations cause gain-of-function
effects mimicking themolecular defects caused by bi-allelic
mutations in ORC1, ORC4, ORC6, CDT1, or CDC6, leading
to autosomal-dominant MGS.
Alternative potential mechanisms of action include that
the disease is caused by an autosomal-recessive paradigm
like observed for the other pre-replication complex defects
and that the second mutation lies within deep intronic re-
gions or regulatory regions not covered by exome or
Sanger analysis. However, the function of geminin as an
inhibitor of replication is not consistent with such a
mechanism and thus an undetected mutation seems the
least likely mechanism to account for the phenotype of
these individuals. Additionally, all three mutations that
we identified in GMNN are de novo, which would be
extremely rare for autosomal-recessive disorders, suggest-
ing further that an undetected second mutation is
unlikely.
The three subjects in this study with de novo mutations
in GMNN have classic features of primordial dwarfism, mi-
crotia, and absent patellae, fulfilling the clinical diag-
nostic criteria of MGS. Prior studies of individuals with
mutations in ORC1, ORC4, ORC6, CDT1, or CDC6 have
noted that individuals with ORC1 mutations were shorter
in stature and had a smaller head circumference compared
to individuals with mutations in the other four genes.4
Relative to published cohorts, individuals with de novo
mutations in GMNN described herein are also on the
extreme end of the height spectrum with a height Z scoreThe Americanranging from 3.9 to 6.8. In addition, subjects 2 and 3
have marked lumbar lordosis and developmental delay
and/or cognitive impairment, a rare finding in MGS.
Moreover, subjects 1 and 2 share fullness of the peri-
orbital region, not previously recognized in other individ-
uals with MGS who have mutations in the five known
genes. Based on the severity of the phenotype, we specu-
late that ORC1 and GMNN mutations might perturb DNA
replication to a greater extent than the other MGS associ-
ated genes, and perhaps GMNN mutations have a more
profound effect on the replicative burst and cell growth
required for brain development, head size expansion,
and height.
In conclusion, we describe an autosomal-dominant
form of MGS resulting from de novo heterozygous muta-
tions in GMNN, likely caused by a gain-of-function
mechanism in replication inhibitor geminin. These de
novo GMNN mutations lead to more stable geminin pro-
teins that lack the intact destruction box and interfere
with the cell cycle. We speculate that other types of mu-
tations such as small in-frame deletions or missense
changes that affect the normal function of the destruc-
tion box might also cause MGS. Mutations in GMNN
should be considered in individuals with MGS who do
not have contributing mutations in one of the genes
associated with the autosomal-recessive form of MGS.
The identification of autosomal-dominant MGS caused
by defects in GMNN in this study expands the genetic
heterogeneity of this disorder, helps identify the mol-
ecular etiology in additional individuals with MGS,
and provides further insights into the relationship be-
tween DNA replication, cell growth, and organismal
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